Author of

• 15209

  +

  P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15240

    +

    P3.01-031 - Prognosis Factors in Stage IV Lung Adenocarcinoma with Single Brain Metastasis (ID 2907)

    09:30 - 09:30  |  Author(s): I.C. Miron
    • Abstract

    Background:
    With the change of lung cancer epidemiology, the frequency of lung adenocarcinoma is steadily increasing. This histological subtype is often associated with brain metastasis, which negatively impact survival. Standard treatment for single-brain metastasis includes surgery, radiotherapy and platinum-based chemotherapy. However, this approach is often associated with acute and chronic toxicity and may negatively impact quality of life in these patients. We need simple prognosis factors to better determine which patients will benefit from this combined therapy.
    
    Methods:
    We performed a retrospective analysis of all lung cancer patients treated in the Oncology department of the Regional Oncology Institute, Iaşi, Romania between January 2012 and January 2014. Inclusion criteria: ECOG 1-2, stage IV lung adenocarcinoma with single-brain metastasis that underwent surgery and radiotherapy for the brain metastasis, followed by systemic treatment with a platinum-based regimen. Data were collected for each patient: age, sex, metastasis size and localization, neurological symptoms, the presence of other secondary lesions at diagnosis, concurrent illnesses, hemoglobin levels, white blood cells, platelets and lactate dehydrogenase (at the time of diagnosis). Data were analyzed by means of SPSS v.20 software - Cox regression. Continuous variables are expressed as mean±SE. Statistical significance was set at .05.
    
    Results:
    31 patients met the inclusion criteria. Mean age was 58.6±1.55 years. Overall survival (OS) was 266±28.32 days. Cox regression analysis indicated that a high white blood cell count, extra-cerebral metastatic sites, age and pre-existing illnesses negatively impact OS (p<0.05). In contrast, symptoms, localization and size of the brain metastasis, as well as hemoglobin, lactate dehydrogenase and platelets had no impact on OS in this analysis. Patients with a high white blood cell count (n=13) had an average OS of 168.3±35.3 days as compared with 336±33.2 days in patients with normal white blood cell count at diagnosis (n=18).
    
    Conclusion:
    As more and more aggressive therapeutic strategies emerge, we need simple and effective parameters that can predict survival in order to select the best approach for each individual patient. High white blood cell count, extra-cerebral metastatic sites, age and pre-existing illnesses were associated with decreased OS. A future prospective study is warranted to confirm our results.